Diabetic kidney disease (DKD) remains one of the most devastating microvascular complications of diabetes mellitus, affecting approximately 30–40 % of patients with both type 1 and type 2 diabetes. It is the leading cause of end‑stage renal disease (ESRD) worldwide, placing an enormous burden on patients and healthcare systems. Although hyperglycemia, hypertension, and genetic susceptibility have long been recognized as key drivers, the molecular underpinnings of DKD are far from fully understood. Over the past decade, a class of small non‑coding RNA molecules called microRNAs (miRNAs) has emerged as critical regulators of the pathogenic processes that culminate in DKD. These tiny, roughly 22‑nucleotide‑long RNA sequences fine‑tune gene expression at the post‑transcriptional level and are now known to influence inflammation, fibrosis, apoptosis, and other cellular events that drive kidney injury. This article provides a comprehensive overview of the role of miRNAs in DKD, from their biosynthesis and mechanisms of action to their potential as diagnostic biomarkers and therapeutic targets.

MicroRNA Biogenesis and Mechanism of Action

MicroRNAs are transcribed primarily by RNA polymerase II as long primary transcripts (pri‑miRNAs) that contain a hairpin structure. Within the nucleus, the microprocessor complex—comprising the RNase III enzyme Drosha and its cofactor DGCR8—cleaves the pri‑miRNA to release a ~70‑nucleotide precursor miRNA (pre‑miRNA). The pre‑miRNA is exported to the cytoplasm via exportin‑5, where it is further processed by another RNase III enzyme, Dicer, yielding a mature miRNA duplex. One strand of the duplex, the guide strand, is loaded into the RNA‑induced silencing complex (RISC), while the passenger strand is typically degraded. The mature miRNA guides RISC to complementary sequences predominantly located in the 3′ untranslated region (UTR) of target messenger RNAs (mRNAs). This interaction leads either to translational repression or to mRNA destabilization and degradation, depending on the degree of complementarity. Through this mechanism, a single miRNA can regulate the expression of hundreds of different genes, thereby exerting broad control over cellular networks.

The versatility of miRNA‑mediated regulation is essential for normal kidney development and homeostasis. However, in the diabetic milieu—characterized by hyperglycemia, advanced glycation end‑products (AGEs), oxidative stress, and pro‑inflammatory cytokines—the expression profiles of many miRNAs become dysregulated. This dysregulation contributes directly to the pathological features of DKD, including glomerular hypertrophy, mesangial expansion, tubulointerstitial fibrosis, and podocyte injury.

MicroRNA Dysregulation in Diabetic Kidney Disease

Inflammation

Chronic low‑grade inflammation is a hallmark of DKD. Several miRNAs modulate the inflammatory cascade by targeting key signaling pathways such as nuclear factor‑κB (NF‑κB) and Janus kinase/signal transducers and activators of transcription (JAK/STAT). Among the most studied are miR‑146a and miR‑155. miR‑146a acts as a negative feedback regulator of NF‑κB activation by targeting interleukin‑1 receptor‑associated kinase 1 (IRAK1) and TNF receptor‑associated factor 6 (TRAF6). In DKD, miR‑146a is often downregulated, leading to sustained NF‑κB activity and increased production of pro‑inflammatory cytokines such as tumor necrosis factor‑α (TNF‑α) and interleukin‑6 (IL‑6). Conversely, miR‑155 is frequently upregulated in response to hyperglycemia and promotes inflammation by targeting suppressors of cytokine signaling (SOCS) proteins, thereby enhancing JAK/STAT signaling. The balance between pro‑inflammatory and anti‑inflammatory miRNAs is thus critical in determining the extent of renal inflammation.

Fibrosis

Renal fibrosis, characterized by excessive accumulation of extracellular matrix (ECM) components, is the final common pathway in DKD leading to ESRD. Transforming growth factor‑β1 (TGF‑β1) is the master profibrotic cytokine in the kidney, and many miRNAs are either downstream effectors or upstream regulators of TGF‑β1 signaling. miR‑21 is consistently found upregulated in kidney biopsies and urine from DKD patients. It promotes fibrosis by targeting multiple negative regulators of TGF‑β signaling, including Smad7 and phosphatase and tensin homolog (PTEN). Moreover, miR‑21 enhances the expression of ECM proteins such as collagen and fibronectin. In contrast, miR‑29 family members (miR‑29a, miR‑29b, miR‑29c) are potent anti‑fibrotic miRNAs that directly suppress the expression of collagens, fibrillins, and other ECM genes. miR‑29 is typically downregulated in DKD, relieving its repression of ECM synthesis. Restoring miR‑29 levels in experimental models attenuates renal fibrosis. Another important miRNA is miR‑192, which is enriched in the kidney and regulates TGF‑β‑induced collagen deposition. miR‑192 expression is altered in diabetic conditions, and it contributes to the amplification of fibrotic signals through cross‑talk with other miRNAs such as miR‑200 family members.

Podocyte Injury and Apoptosis

Podocytes are highly specialized epithelial cells that form the glomerular filtration barrier. Their injury and loss are early events in DKD and strongly predict proteinuria and disease progression. Several miRNAs are crucial for maintaining podocyte health. miR‑29c, besides its anti‑fibrotic role, also protects podocytes from apoptosis by targeting the pro‑apoptotic protein Bcl‑2‑associated X (BAX). Conversely, miR‑21 promotes podocyte apoptosis through PTEN inhibition and subsequent activation of the PI3K/Akt pathway. miR‑193a has been identified as a key regulator of podocyte differentiation; its overexpression leads to podocyte dedifferentiation and foot process effacement, a hallmark of proteinuric kidney diseases. Additionally, miR‑30 family members are highly expressed in podocytes and are essential for their survival. In diabetic conditions, miR‑30 expression is downregulated, contributing to podocyte apoptosis and glomerulosclerosis.

Tubulointerstitial Injury

While glomerular damage is the classic feature of DKD, tubulointerstitial injury is equally important and correlates more closely with renal function decline. miRNAs also operate in tubular epithelial cells, influencing epithelial‑mesenchymal transition (EMT), tubular atrophy, and interstitial fibrosis. miR‑200 family members (miR‑200a, miR‑200b, miR‑200c, miR‑141, miR‑429) are key regulators of EMT through suppression of zinc‑finger E‑box‑binding homeobox 1 (ZEB1) and ZEB2. In DKD, miR‑200 expression is reduced, promoting EMT and subsequent fibrosis. miR‑214 and miR‑382 have also been implicated in tubular injury by targeting phosphatase and tensin homolog (PTEN) and augmenting collagen production. Furthermore, tubular cells can release miRNAs into the urine via exosomes, providing a non‑invasive window into the disease状态.

Key MicroRNAs in DKD: A Closer Look

miR‑21

miR‑21 is arguably the most extensively studied miRNA in DKD. It is consistently upregulated in glomerular mesangial cells, podocytes, and tubular epithelial cells in response to high glucose, TGF‑β, and other stressors. Its pro‑fibrotic and pro‑apoptotic actions are mediated through inhibition of PTEN, Smad7, and programmed cell death 4 (PDCD4). Numerous animal studies have shown that genetic deletion or pharmacological inhibition of miR‑21 significantly attenuates proteinuria, glomerulosclerosis, and tubulointerstitial fibrosis in diabetic mouse models. Because of its central role, miR‑21 is currently being explored as a therapeutic target in human clinical trials for fibrotic diseases, including DKD.

miR‑29 Family

The miR‑29 family (miR‑29a, -29b, -29c) acts as a natural brake on fibrosis by directly repressing multiple collagen genes (COL1A1, COL1A2, COL3A1) and other ECM components. In DKD, miR‑29 expression is suppressed by TGF‑β and NF‑κB. Restoring miR‑29 levels with synthetic mimics reduces ECM accumulation and protects renal function in rodent models. Low circulating levels of miR‑29 have also been associated with a higher risk of progression to ESRD in diabetic patients, suggesting its potential as a prognostic biomarker.

miR‑192

miR‑192 is highly expressed in the kidney and was one of the first miRNAs linked to diabetic nephropathy. It is induced by TGF‑β and serves as a positive regulator of collagen synthesis. However, its role appears context‑dependent: some studies report that miR‑192 exacerbates fibrosis, while others suggest it may have protective effects in certain cell types. This duality highlights the complexity of miRNA networks and the need for cell‑type‑specific analyses.

miR‑146a

As a key negative regulator of inflammation, miR‑146a is protective against DKD. Its downregulation in diabetic kidneys is associated with increased NF‑κB activity and monocyte chemoattractant protein‑1 (MCP‑1) expression. Overexpression of miR‑146a in mesangial cells reduces high‑glucose‑induced inflammation, and its systemic delivery via viral vectors ameliorates renal injury in diabetic mice. Therefore, strategies to upregulate miR‑146a could be beneficial.

miR‑200 Family

The miR‑200 family is essential for maintaining the epithelial phenotype by suppressing EMT‑inducing transcription factors ZEB1 and ZEB2. In DKD, miR‑200 members are downregulated, facilitating tubular cell dedifferentiation and fibrosis. Moreover, miR‑200c also targets the pro‑apoptotic factor Fas‑associated death domain (FADD), thereby influencing cell survival. The interplay between miR‑200 and miR‑192 forms a regulatory loop that amplifies TGF‑β signaling.

Clinical Implications and Translational Potential

Circulating miRNAs as Biomarkers

One of the most promising aspects of miRNA research in DKD is the development of non‑invasive biomarkers. MiRNAs are remarkably stable in body fluids such as serum, plasma, and urine because they are protected by encapsulation in exosomes, microvesicles, or binding to Argonaute proteins. Numerous studies have reported altered levels of specific circulating miRNAs in DKD patients compared to diabetic controls or healthy individuals. For instance, elevated levels of miR‑21 and miR‑192 in urine predict the progression of microalbuminuria to macroalbuminuria and decline in estimated glomerular filtration rate (eGFR). Conversely, low levels of miR‑29 and miR‑146a in serum are associated with more severe renal fibrosis. The combination of multiple miRNAs into a panel may improve diagnostic accuracy beyond conventional markers like albuminuria and eGFR.

Therapeutic Targeting of miRNAs

The ability to manipulate miRNA levels offers a novel therapeutic strategy for DKD. Two main approaches are being pursued: inhibition of pathogenic miRNAs (e.g., using antagomirs, locked nucleic acid (LNA)‑modified antisense oligonucleotides, or CRISPR‑based tools) and replacement of protective miRNAs (using synthetic miRNA mimics). Preclinical studies have demonstrated the efficacy of these strategies. For example, subcutaneous administration of an LNA‑modified anti‑miR‑21 oligonucleotide reduced fibrosis and improved renal function in a mouse model of Alport syndrome—a genetic kidney disease that shares fibrotic features with DKD. Similar approaches are now being tested in DKD models. Phase 2 clinical trials are underway for anti‑miR‑21 in other fibrotic conditions, and the outcomes will inform future trials in DKD. Additionally, delivery of miR‑29 mimics using lipid nanoparticles has shown promise in pre‑clinical fibrosis models.

However, several challenges remain. Off‑target effects are a major concern because a single miRNA regulates many genes. Systemic delivery may lead to unwanted effects in other organs. Kidney‑specific delivery systems, such as targeted nanoparticles or adeno‑associated viral (AAV) vectors with kidney‑tropic serotypes, are under active development. Moreover, the chronic nature of DKD would likely require long‑term treatment, raising questions about safety and durability of response.

Integration with Existing Therapies

While renin‑angiotensin‑aldosterone system (RAAS) blockade and glucose control remain the cornerstones of DKD treatment, they are insufficient to halt disease progression in many patients. MiRNA‑based therapies could complement these standard treatments. For example, combining an anti‑miR‑21 agent with an ACE inhibitor or an SGLT2 inhibitor may provide additive or synergistic renoprotective effects. Understanding the interplay between miRNAs and current drugs is an important area of ongoing investigation. Furthermore, miRNAs may help identify patients who are most likely to benefit from specific therapies, enabling a personalized medicine approach.

Future Directions

The field of miRNA research in DKD is rapidly evolving. Single‑cell RNA sequencing technologies are now revealing the cell‑type‑specific expression patterns of miRNAs in the diabetic kidney, which will help resolve conflicting data and identify the most relevant targets. High‑throughput profiling of circulating miRNAs combined with machine learning algorithms may yield robust diagnostic and prognostic panels for clinical use. Moreover, the advent of CRISPR‑Cas systems allows for precise editing of miRNA expression levels in vivo, opening new possibilities for permanent correction of dysregulated networks. Finally, the discovery of additional regulatory layers—such as circular RNAs (circRNAs) and long non‑coding RNAs (lncRNAs) that act as miRNA sponges—adds complexity but also new opportunities for therapeutic intervention. As our understanding deepens, miRNAs are poised to become integral components of the diagnostic and therapeutic armamentarium against diabetic kidney disease.

Conclusion

MicroRNAs are central players in the pathogenesis of diabetic kidney disease, orchestrating the inflammatory, fibrotic, and apoptotic processes that drive renal injury. The dysregulation of specific miRNAs—such as the upregulation of miR‑21 and downregulation of miR‑29, miR‑146a, and miR‑200—directly contributes to disease progression. These small RNAs not only serve as promising biomarkers for early detection and risk stratification but also represent viable therapeutic targets. While challenges remain in translating miRNA‑based drugs to the clinic, the convergence of advanced delivery technologies, improved target validation, and a deeper understanding of miRNA biology holds great promise. With continued research, miRNA‑based diagnostics and therapeutics may soon change the landscape of DKD management, offering new hope to millions of patients worldwide.